Exact Mass: 429.3831

Exact Mass Matches: 429.3831

Found 57 metabolites which its exact mass value is equals to given mass value 429.3831, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

3-Hydroxyheptadecanoylcarnitine

3-[(3-hydroxyheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO5 (429.3454)


3-Hydroxyheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Hydroxyheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-Hydroxyheptadecanoylcarnitine

3-[(10-Hydroxyheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C24H47NO5 (429.3454)


10-Hydroxyheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-hydroxyheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxyheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 10-Hydroxyheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-Hydroxyheptadecanoylcarnitine

3-[(11-hydroxyheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO5 (429.3454)


11-Hydroxyheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-hydroxyheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-Hydroxyheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-Hydroxyheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

12-Hydroxyheptadecanoylcarnitine

3-[(12-hydroxyheptadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO5 (429.3454)


12-Hydroxyheptadecanoylcarnitine is an acylcarnitine. More specifically, it is an 12-hydroxyheptadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-Hydroxyheptadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 12-Hydroxyheptadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Carbamoyl cholesterol

7-(3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-3-methyloctanamide

C28H47NO2 (429.3607)


   

Dihydroimpranine

Dihydroimpranine

C28H47NO2 (429.3607)


   
   

5alpha-Methyleduardinine

5alpha-Methyleduardinine

C28H47NO2 (429.3607)


   
   
   

20alpha-Dimethylamino-3beta-(3-methyl-crotonoyloxy)-5alpha-pregnan|20alpha-Dimethylamino-3beta-<3-methyl-crotonoyloxy>-5alpha-pregnan

20alpha-Dimethylamino-3beta-(3-methyl-crotonoyloxy)-5alpha-pregnan|20alpha-Dimethylamino-3beta-<3-methyl-crotonoyloxy>-5alpha-pregnan

C28H47NO2 (429.3607)


   

Edpetilidinine

Edpetilidinine

C28H47NO2 (429.3607)


   
   

3beta-Hydroxy-5alpha-cholest-8-ene-4alpha-carboxylate

3beta-Hydroxy-5alpha-cholest-8-ene-4alpha-carboxylate

C28H45O3- (429.3369)


A steroid acid anion that is the conjugate base of 3beta-hydroxy-5alpha-cholest-8-ene-4alpha-carboxylic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(3S,4S,5S,9R,10S,13R,14R,17R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-4-carboxylate

(3S,4S,5S,9R,10S,13R,14R,17R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-4-carboxylate

C28H45O3- (429.3369)


   

3-Hydroxyheptadecanoylcarnitine

3-Hydroxyheptadecanoylcarnitine

C24H47NO5 (429.3454)


   

10-Hydroxyheptadecanoylcarnitine

10-Hydroxyheptadecanoylcarnitine

C24H47NO5 (429.3454)


   

11-Hydroxyheptadecanoylcarnitine

11-Hydroxyheptadecanoylcarnitine

C24H47NO5 (429.3454)


   

12-Hydroxyheptadecanoylcarnitine

12-Hydroxyheptadecanoylcarnitine

C24H47NO5 (429.3454)


   

4alpha-carboxy-5alpha-cholest-7-en-3beta-ol

4alpha-carboxy-5alpha-cholest-7-en-3beta-ol

C28H45O3- (429.3369)


   

N-Methyltomatidine

N-Methyltomatidine

C28H47NO2 (429.3607)


   

2-Aminohexacosane-1,3,4-triol

2-Aminohexacosane-1,3,4-triol

C26H55NO3 (429.4182)


   

Cer 9:0;3O/15:1;(2OH)

Cer 9:0;3O/15:1;(2OH)

C24H47NO5 (429.3454)


   

Cer 8:0;3O/16:1;(2OH)

Cer 8:0;3O/16:1;(2OH)

C24H47NO5 (429.3454)


   

Cer 12:0;3O/12:1;(2OH)

Cer 12:0;3O/12:1;(2OH)

C24H47NO5 (429.3454)


   

Cer 10:0;3O/14:1;(2OH)

Cer 10:0;3O/14:1;(2OH)

C24H47NO5 (429.3454)


   

Cer 12:1;3O/12:0;(2OH)

Cer 12:1;3O/12:0;(2OH)

C24H47NO5 (429.3454)


   

Cer 11:0;3O/13:1;(2OH)

Cer 11:0;3O/13:1;(2OH)

C24H47NO5 (429.3454)


   

(11Z,14Z,17Z,20Z,23Z)-N-(2-hydroxyethyl)hexacosa-11,14,17,20,23-pentaenamide

(11Z,14Z,17Z,20Z,23Z)-N-(2-hydroxyethyl)hexacosa-11,14,17,20,23-pentaenamide

C28H47NO2 (429.3607)


   

NA-Histamine 22:2(13Z,16Z)

NA-Histamine 22:2(13Z,16Z)

C27H47N3O (429.3719)


   

Hexacosapentaenoyl-EA

Hexacosapentaenoyl-EA

C28H47NO2 (429.3607)


   
   

Cer 14:0;O2/11:0;2OH

Cer 14:0;O2/11:0;2OH

C25H51NO4 (429.3818)


   

Cer 14:0;O2/11:0;3OH

Cer 14:0;O2/11:0;3OH

C25H51NO4 (429.3818)


   

Cer 14:0;O2/11:0;O

Cer 14:0;O2/11:0;O

C25H51NO4 (429.3818)


   

Cer 15:0;O2/10:0;2OH

Cer 15:0;O2/10:0;2OH

C25H51NO4 (429.3818)


   

Cer 15:0;O2/10:0;3OH

Cer 15:0;O2/10:0;3OH

C25H51NO4 (429.3818)


   

Cer 15:0;O2/10:0;O

Cer 15:0;O2/10:0;O

C25H51NO4 (429.3818)


   

Cer 18:0;O2/7:0;2OH

Cer 18:0;O2/7:0;2OH

C25H51NO4 (429.3818)


   

Cer 18:0;O2/7:0;3OH

Cer 18:0;O2/7:0;3OH

C25H51NO4 (429.3818)


   

Cer 18:0;O2/7:0;O

Cer 18:0;O2/7:0;O

C25H51NO4 (429.3818)


   

Cer 14:0;O3/11:0

Cer 14:0;O3/11:0

C25H51NO4 (429.3818)


   

Cer 15:0;O3/10:0

Cer 15:0;O3/10:0

C25H51NO4 (429.3818)


   
   

(1s,3as,3bs,5as,7s,9ar,9bs,11as)-1-[(1s)-1-[(2s,5r)-1,5-dimethylpiperidin-2-yl]ethyl]-7-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one

(1s,3as,3bs,5as,7s,9ar,9bs,11as)-1-[(1s)-1-[(2s,5r)-1,5-dimethylpiperidin-2-yl]ethyl]-7-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one

C28H47NO2 (429.3607)


   

(1r,2s,3as,3bs,7s,9ar,9bs,11as)-1-[(1s)-1-[(2s,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

(1r,2s,3as,3bs,7s,9ar,9bs,11as)-1-[(1s)-1-[(2s,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

C28H47NO2 (429.3607)


   

(3as,3bs,5ar,7s,9ar,9bs,11as)-1-[(1s)-1-(1,5-dimethylpiperidin-2-yl)ethyl]-7-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one

(3as,3bs,5ar,7s,9ar,9bs,11as)-1-[(1s)-1-(1,5-dimethylpiperidin-2-yl)ethyl]-7-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one

C28H47NO2 (429.3607)


   

(3s,4as,5r,6ar,6bs,9s,10ar,11as,11br)-9-[(1s)-1-[(2r,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-10a,11b-dimethyl-1h,2h,3h,4h,4ah,5h,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluorene-3,5-diol

(3s,4as,5r,6ar,6bs,9s,10ar,11as,11br)-9-[(1s)-1-[(2r,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-10a,11b-dimethyl-1h,2h,3h,4h,4ah,5h,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluorene-3,5-diol

C28H47NO2 (429.3607)


   

1-[(1e)-2-(1,5-dimethylpiperidin-2-yl)ethenyl]-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthrene-5,7-diol

1-[(1e)-2-(1,5-dimethylpiperidin-2-yl)ethenyl]-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthrene-5,7-diol

C28H47NO2 (429.3607)


   

(2s,3as,3bs,7s,9ar,9bs,11as)-1-[(1s)-1-(1,5-dimethylpiperidin-2-yl)ethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

(2s,3as,3bs,7s,9ar,9bs,11as)-1-[(1s)-1-(1,5-dimethylpiperidin-2-yl)ethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

C28H47NO2 (429.3607)


   

1-[1-(1,5-dimethylpiperidin-2-yl)ethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

1-[1-(1,5-dimethylpiperidin-2-yl)ethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

C28H47NO2 (429.3607)


   

9-[1-(1,5-dimethylpiperidin-2-yl)ethyl]-10a,11b-dimethyl-1h,2h,3h,4h,4ah,5h,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluorene-3,5-diol

9-[1-(1,5-dimethylpiperidin-2-yl)ethyl]-10a,11b-dimethyl-1h,2h,3h,4h,4ah,5h,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluorene-3,5-diol

C28H47NO2 (429.3607)


   

(1r,2r,3as,3bs,7r,9ar,9bs,11as)-1-[(1s)-1-[(2r,5r)-1,5-dimethylpiperidin-2-yl]ethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

(1r,2r,3as,3bs,7r,9ar,9bs,11as)-1-[(1s)-1-[(2r,5r)-1,5-dimethylpiperidin-2-yl]ethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-diol

C28H47NO2 (429.3607)


   

(1s,2s,3ar,3bs,7s,9ar,9bs,11ar)-1-[(1s)-1-[(2s,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-1,9a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h,11ah-cyclopenta[a]phenanthrene-2,7-diol

(1s,2s,3ar,3bs,7s,9ar,9bs,11ar)-1-[(1s)-1-[(2s,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-1,9a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h,11ah-cyclopenta[a]phenanthrene-2,7-diol

C28H47NO2 (429.3607)


   

9a,11a-dimethyl-1-[1-(1-methylazepan-2-yl)ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3,7-diol

9a,11a-dimethyl-1-[1-(1-methylazepan-2-yl)ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3,7-diol

C28H47NO2 (429.3607)


   

(3s,4as,5r,6ar,6br,9s,10ar,11as,11br)-9-[(1s)-1-[(2r,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-10a,11b-dimethyl-1h,2h,3h,4h,4ah,5h,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluorene-3,5-diol

(3s,4as,5r,6ar,6br,9s,10ar,11as,11br)-9-[(1s)-1-[(2r,5s)-1,5-dimethylpiperidin-2-yl]ethyl]-10a,11b-dimethyl-1h,2h,3h,4h,4ah,5h,6h,6ah,6bh,9h,10h,11h,11ah-cyclohexa[a]fluorene-3,5-diol

C28H47NO2 (429.3607)